Hydroxychloroquine has been prescribed for lupus, rheumatoid arthritis, and malaria for more than sixty years, which means its safety profile is unusually well documented compared to newer drugs. This article lays out what that long record actually shows: the common side effects most patients notice, the rarer but serious risks that require monitoring, what happens in overdose, who should not take it, and how the drug performed in the large trials that tested it against COVID-19. The goal is not to reassure or alarm, but to give readers the same information a careful physician would want on the table before prescribing it.

A Long Clinical History Worth Understanding

Hydroxychloroquine is a synthetic derivative of quinine, the compound first isolated from the bark of the cinchona tree, a plant indigenous to South America that has treated fevers for centuries. It is a fair thing to notice that some of medicine's most durable tools came not from a laboratory dreamed up from nothing, but from careful observation of what the created world already offered. Chloroquine, its close chemical cousin, came into wide use during and after the Second World War; hydroxychloroquine followed as a somewhat gentler variant, approved by the FDA in 1955 and sold under the brand name Plaquenil, among others.

Its approved uses today are malaria prevention and treatment, rheumatoid arthritis, and systemic and discoid lupus erythematosus. It is not a broad-spectrum antiviral, and outside of malaria it is not approved as a treatment for any viral infection, a point worth stating plainly given how often it surfaces in unrelated conversations. Its mechanism in autoimmune disease involves accumulating in intracellular compartments called lysosomes, raising their pH, and dampening the immune signaling that drives lupus flares and joint inflammation. That mechanism is well established in cell and animal studies and corroborated by decades of clinical use in rheumatology.

The Side Effects Most Patients Actually Experience

For the majority of people who take hydroxychloroquine at standard doses, side effects are mild and gastrointestinal. Clinical trial data compiled across rheumatology and lupus studies consistently show the following as the most frequent complaints:

These effects lead a meaningful minority of patients to stop the drug, but they are rarely dangerous. The more consequential risks lie further down the list, are less common, and are the reason hydroxychloroquine requires ongoing medical supervision rather than casual, unsupervised use.

The Risks That Require Real Monitoring

The single most important long-term risk is retinal toxicity, commonly called hydroxychloroquine retinopathy. The drug accumulates gradually in the pigmented layer of the retina, and over years of use it can damage the light-sensing cells, producing a characteristic pattern of vision loss sometimes described as a "bull's-eye" appearance on retinal imaging. Early stages are often asymptomatic, which is precisely why screening matters.

A widely cited cohort study from Kaiser Permanente, published in JAMA Ophthalmology in 2014 by Melles and Marmor, examined long-term users and found that overall retinopathy risk was low in the first five years of use, well under two percent, but rose substantially with cumulative duration and dose, reaching roughly one in five patients after two decades of continuous use at higher doses. Based on findings like this, the American Academy of Ophthalmology revised its screening guidance in 2016, recommending a baseline eye exam when starting the drug and annual screening after five years of use, sooner for patients with additional risk factors such as reduced kidney function, higher body-weight-adjusted dosing, pre-existing retinal disease, or concurrent use of tamoxifen. The current dosing standard of no more than roughly 5 milligrams per kilogram of actual body weight per day was adopted specifically to bring this risk down, and it has meaningfully reduced retinopathy rates compared to older, higher-dose regimens.

Cardiac effects are less common but deserve mention. Hydroxychloroquine can prolong the QT interval, a measure of the heart's electrical recovery time, which in susceptible individuals can predispose to dangerous arrhythmias, particularly when combined with other QT-prolonging medications. Rare case reports and case series in the cardiology literature also describe hydroxychloroquine-associated cardiomyopathy, a thickening or weakening of the heart muscle, typically after many years of high cumulative exposure; this is uncommon but often reversible if caught and the drug is stopped. Patients with pre-existing heart rhythm disorders or those taking other QT-prolonging drugs should discuss this specifically with their physician.

Blood sugar can also drop unexpectedly, since hydroxychloroquine has a mild insulin-sensitizing effect; this matters most for patients on insulin or sulfonylurea medications for diabetes, who should watch for hypoglycemia symptoms after starting the drug. Hemolytic anemia is a rare but recognized risk in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme condition that makes red blood cells more fragile under oxidative stress; the risk is considerably lower with hydroxychloroquine than with related antimalarials like primaquine, but it is still worth checking for in patients with a personal or family history suggestive of the condition.

Allergic Reactions and Overdose: Where the Real Danger Lies

True allergic reactions to hydroxychloroquine are uncommon. Most skin reactions are mild rashes that resolve with dose adjustment or discontinuation. Rarely, more severe hypersensitivity reactions occur, including Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), which involve widespread skin blistering, fever, and organ involvement. These are medical emergencies, though they are rare events reported in the pharmacovigilance literature rather than a common outcome of treatment.

Overdose is a different matter and deserves direct, unhurried attention, because hydroxychloroquine has a narrow margin between a therapeutic dose and a dangerous one. Unlike many common medications, an overdose of hydroxychloroquine, whether accidental or intentional, can be lethal within hours. Toxicology literature on 4-aminoquinoline overdose describes a rapid progression: profound low blood pressure, life-threatening heart rhythm disturbances, low potassium levels, and seizures, sometimes appearing before a patient reaches a hospital. This is why poison control centers treat any suspected hydroxychloroquine overdose as an emergency requiring immediate evaluation, generally with cardiac monitoring, and why the medication should be stored securely, away from children and anyone at risk of self-harm. Treatment in overdose can include specific interventions such as epinephrine, sodium bicarbonate, and benzodiazepines, administered in a hospital setting; this is not something to manage at home. The lesson for ordinary use is straightforward: take the medication exactly as prescribed, store it responsibly, and never share it or increase the dose without medical guidance.

Who Should Avoid Hydroxychloroquine

Certain patients should not take hydroxychloroquine, or should only do so with careful specialist oversight:

One area where the data is reassuring rather than restrictive is pregnancy. Unlike many immunosuppressive drugs used for lupus and rheumatoid arthritis, hydroxychloroquine has an unusually favorable pregnancy safety record. Cohort data from lupus pregnancy registries, including long-running work associated with the Hopkins Lupus Cohort, has not shown an increased rate of major birth defects, and continuing the drug through pregnancy is associated with fewer lupus flares and better outcomes for both mother and baby. The American College of Rheumatology recommends continuing hydroxychloroquine during pregnancy for most patients with lupus. This is a genuine point of confidence in the data, not a marketing claim, and it stands as a good example of a medication whose real-world track record, rather than assumption, should guide a mother's decision in conversation with her physician.

What the Large Trials Showed for COVID-19

No honest safety article can ignore the reason hydroxychloroquine became a household name in 2020. During the early pandemic, small and largely uncontrolled studies raised interest in hydroxychloroquine as a possible treatment for COVID-19. That question was subsequently tested properly. The RECOVERY trial, a large randomized controlled trial run by the University of Oxford and published in the New England Journal of Medicine in 2020, enrolled thousands of hospitalized COVID-19 patients and found no reduction in mortality among those given hydroxychloroquine; the hydroxychloroquine arm was closed early because the data showed no benefit. The World Health Organization's SOLIDARITY trial reached a similar conclusion. On the strength of this evidence, the FDA revoked its emergency authorization for hydroxychloroquine in COVID-19 in June 2020, citing both lack of efficacy and safety concerns, particularly cardiac arrhythmia risk in hospitalized patients, some of whom were also receiving other QT-prolonging drugs. Hydroxychloroquine is not an approved or recommended treatment for COVID-19. This is simply what the randomized evidence showed, and it does not reflect on the drug's established, decades-long record in lupus and rheumatoid arthritis, where the benefit-risk balance remains well understood and favorable for appropriately selected patients.

Key takeaway: Hydroxychloroquine has a long, well-studied safety record for lupus and rheumatoid arthritis, with manageable common side effects and a small but serious risk of retinal and cardiac harm that responsible monitoring is designed to catch early, and patients should always take it under a physician's guidance rather than on their own initiative.